Back to discover
Disease

Glucose Metabolism Disorders

Late-stage therapeutic developmentEmerging research
MeSHGlucose Metabolism Disorders
2
Publications
18
Clinical trials
1
Related treatments
2019
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Major developments
Upcoming trial readoutImportant
Regulation of Endogenous Glucose Production by Central KATP Channels
Results expected Q2 20272026-04-28
Clinical Milestones1View
Results expected 1
Activity timeline1

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

15 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
18
All trials
4
Active
10
Late-stage
6
Completed
Late-stage studies

The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes

Phase 2/3 · Recruiting · Jaeb Center for Health Research

Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes

Phase 4 · Completed · SINA Health Education and Welfare Trust

Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study)

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

Phase 4 · Completed · US Department of Veterans Affairs

Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance

Phase 4 · Withdrawn · University of Leipzig

Comparison of Oral Semaglutide With Matched Oral Semaglutide Placebo as an Early Treatment for Latino Adults With Type 2 Diabetes Receiving Enhanced Lifestyle Care

Phase 4 · Terminated · Sansum Diabetes Research Institute
Recently completed

Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes

Phase 4 · Completed · SINA Health Education and Welfare Trust

Acute Metabolic Effects of Melatonin Treatment

Phase 1/2 · Completed · University of Aarhus

The Role of Glucagon-like Peptide-1 Receptor Signalling in the Glucose-lowering Effect of Increased Carbohydrate Content in the Distal Small Intestines After Meal Ingestion in Patients With Type 2 Diabetes

N/A · Completed · University Hospital, Gentofte, Copenhagen

The Effect of Glucagon-like Peptide-1 (GLP-1) on Cognitive and Non-cognitive Function in Human

N/A · Completed · University of Pisa

Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study)

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

Phase 4 · Completed · US Department of Veterans Affairs

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182019
Major themes1
  • Insulin Resistance1
Leading journals2
  • Cardiovascular diabetology1
  • Cells1
Leading researchers8
  • Aguayo C1
  • Elfeky O1
  • Ferreira V1
  • Grajales D1
  • Nair S1
  • Ormazabal V1
  • Salomon C1
  • Valverde ÁM1
Affiliations (unnormalised)5
  • Department of Clinical Biochemistry and Immunology1
  • Exosome Biology Laboratory1
  • Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM)1
  • Ochsner Baptist Hospital1
  • University of Concepcion1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Pathological conditions in which the BLOOD GLUCOSE cannot be maintained within the normal range, such as in HYPOGLYCEMIA and HYPERGLYCEMIA. Etiology of these disorders varies. Plasma glucose concentration is critical to survival for it is the predominant fuel for the CENTRAL NERVOUS SYSTEM.

Identifiers
MeSHGlucose Metabolism Disorders
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.